person · Reporting owner

Norden Gregory

Disclosed activity across 5 companies

Tapewire entity: 38736
SEC CIK: 0001405104

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Entasis Therapeutics Holdings Inc.ETTX · Entity 16036	Director	June 19, 2019	June 21, 2019
Praxis Precision Medicines, Inc.PRAX · Entity 3538	Director	June 10, 2026	June 12, 2026
Royalty Pharma plcRPRX · Entity 3100	Director	June 05, 2026	June 08, 2026
Zoetis Inc.ZTS · Entity 679	Director	March 09, 2026	March 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Entasis Therapeutics Holdings Inc.

Report date June 19, 2019 · Filed June 21, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.12 · Expires 2029-06-18	Direct	7,500	Reported balance After 2019-06-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-19 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date.

Praxis Precision Medicines, Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,559	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Grant · Acquired 1,371 · Balance 1,559 F1: Mr. Norden was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.66 · Expires 2036-06-10	Direct	648	Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-10 · Grant · Acquired 648 · Balance 648 F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Norden was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Royalty Pharma plc

Report date June 05, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	Direct	196,348	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 196,348 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Zoetis Inc.

Report date March 09, 2026 · Filed March 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2026-03-09 transaction · row 1 1 source row Row 1 · 2026-03-09 · Gift · Disposed 1,213 · Balance 0
Common StockSEC Table I · non-derivative	IndirectBy personal trust	7,071.1922	Reported balance Holding disclosure · report date 2026-03-09 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 7,071.1922 F1: On March 9, 2026, the reporting person transferred 1,213 shares of Zoetis common stock to a trust of which the reporting person is a trustee.
Common StockSEC Table I · non-derivative	IndirectBy daughter's trust	5,548	Reported balance Holding disclosure · report date 2026-03-09 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 5,548
Common StockSEC Table I · non-derivative	IndirectBy son's trust	5,548	Reported balance Holding disclosure · report date 2026-03-09 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 5,548

Filing footnotes · ownership attribution and instrument terms

F1: On March 9, 2026, the reporting person transferred 1,213 shares of Zoetis common stock to a trust of which the reporting person is a trustee.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

NanoString Technologies Inc

Report date May 06, 2024 · Filed May 08, 2024

Section 16 reporting ended · disclosed 2024-05-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	88,552	Reported balance After 2024-05-06 transaction · row 1 1 source row Row 1 · 2024-05-06 · Exercise / conversion · Acquired 41,133 · Balance 88,552 F1: The shares have not been delivered to the reporting person.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-05-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-05-06 · Exercise / conversion · Disposed 41,133 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F3: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated.

Filing footnotes · ownership attribution and instrument terms

F1: The shares have not been delivered to the reporting person.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.

F3: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 10, 2026 Filed Jun 12, 2026 21:23 UTC	Praxis Precision Medicines, Inc. PRAX · Entity 3538	GrantStock Option (Right to Buy) · Derivative	648	$0.00 Strike: $240.66	$0.00	Disclosure SEC source: 0001689548-26-000057 · wk-form4_1781299421.xml · derivative · entry 2 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 648 Underlying: Common Stock · 648 shares Expires 2036-06-10 F2 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:23 UTC	Praxis Precision Medicines, Inc. PRAX · Entity 3538	GrantCommon Stock	1,371	$0.00	$0.00	Disclosure SEC source: 0001689548-26-000057 · wk-form4_1781299421.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,559 F1 · kind: Mr. Norden was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
June 05, 2026 Filed Jun 8, 2026 20:28 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	4,545	$0.00	$0.00	Disclosure SEC source: 0001405104-26-000004 · wk-form4_1780950480.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,348 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document
May 14, 2026 Filed May 15, 2026 20:37 UTC	Royalty Pharma plc RPRX · Entity 3100	SaleClass A Ordinary Shares	3,045	$53.00	$161,385.00	Disclosure SEC source: 0001405104-26-000002 · wk-form4_1778877421.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,803 F1 · kind: The reported transaction was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026. Read SEC document
March 09, 2026 Filed Mar 10, 2026 16:20 UTC	Zoetis Inc. ZTS · Entity 679	GiftCommon Stock	1,213	$0.00	$0.00	Disclosure SEC source: 0001628280-26-016457 · wk-form4_1773174044.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document
February 19, 2026 Filed Feb 23, 2026 16:31 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionRestricted Stock Unit · Derivative	1,619.3325	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-26-010687 · wk-form4_1771882308.xml · derivative · entry 6 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,619.3325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F5 · derivative.exercise_date: Each RSU vests and is settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 19, 2025. F6 · derivative.expiration_date: Not applicable. Read SEC document
February 19, 2026 Filed Feb 23, 2026 16:31 UTC	Zoetis Inc. ZTS · Entity 679	OtherCommon Stock	406	$127.28	$51,675.68	Disclosure SEC source: 0001628280-26-010687 · wk-form4_1771882308.xml · nonDerivative · entry 2 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,213 F2 · kind: Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. Read SEC document
February 19, 2026 Filed Feb 23, 2026 16:31 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionCommon Stock	1,619	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-26-010687 · wk-form4_1771882308.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document
February 18, 2026 Filed Feb 19, 2026 20:53 UTC	Zoetis Inc. ZTS · Entity 679	GrantRestricted Stock Unit · Derivative	1,936	$0.00	$0.00	Disclosure SEC source: 0001628280-26-009972 · wk-form4_1771552408.xml · derivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,936 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 18, 2026; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. Read SEC document
August 11, 2025 Filed Aug 11, 2025 20:35 UTC	Royalty Pharma plc RPRX · Entity 3100	SaleClass A Ordinary Shares	33,500	$36.23	$1,213,748.55	Disclosure SEC source: 0001802768-25-000107 · wk-form4_1754944552.xml · nonDerivative · entry 2 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,848 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.40 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 08, 2025 Filed Aug 11, 2025 20:35 UTC	Royalty Pharma plc RPRX · Entity 3100	ConversionLP interests in RPI US Partners 2019, LP · Derivative	14,466	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001802768-25-000107 · wk-form4_1754944552.xml · derivative · entry 3 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 144,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange. F3 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document
August 08, 2025 Filed Aug 11, 2025 20:35 UTC	Royalty Pharma plc RPRX · Entity 3100	ConversionClass A Ordinary Shares	144,660	$0.00	$0.00	Disclosure SEC source: 0001802768-25-000107 · wk-form4_1754944552.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange. Read SEC document
June 26, 2025 Filed Jun 27, 2025 20:55 UTC	Praxis Precision Medicines, Inc. PRAX · Entity 3538	GrantStock Option (Right to Buy) · Derivative	10,520	$0.00 Strike: $44.04	$0.00	Disclosure SEC source: 0001689548-25-000079 · wk-form4_1751057705.xml · derivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,520 Underlying: Common Stock · 10,520 shares Expires 2035-06-26 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025. Read SEC document
May 13, 2025 Filed May 14, 2025 21:12 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	7,614	$0.00	$0.00	Disclosure SEC source: 0001802768-25-000057 · wk-form4_1747257126.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,688 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document
February 19, 2025 Filed Feb 20, 2025 16:22 UTC	Zoetis Inc. ZTS · Entity 679	GrantRestricted Stock Unit · Derivative	1,596	$0.00	$0.00	Disclosure SEC source: 0001555280-25-000128 · wk-form4_1740086550.xml · derivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,596 Underlying: Common Stock · 1,596 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 19, 2025; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. Read SEC document
February 14, 2025 Filed Feb 18, 2025 16:39 UTC	Zoetis Inc. ZTS · Entity 679	GiftCommon Stock	1,843	$0.00	$0.00	Disclosure SEC source: 0001555280-25-000104 · wk-form4_1739914776.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document
February 08, 2025 Filed Feb 11, 2025 17:13 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionRestricted Stock Unit · Derivative	1,225.4023	Not disclosed	Not disclosed	Disclosure SEC source: 0001555280-25-000085 · wk-form4_1739312010.xml · derivative · entry 6 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,225.4023 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F5 · derivative.exercise_date: Each RSU vests and is settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, February 8, 2022. F6 · derivative.expiration_date: Not applicable. Read SEC document
February 08, 2025 Filed Feb 11, 2025 17:13 UTC	Zoetis Inc. ZTS · Entity 679	OtherCommon Stock	308	$171.43	$52,800.44	Disclosure SEC source: 0001555280-25-000085 · wk-form4_1739312010.xml · nonDerivative · entry 2 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,843 F2 · kind: Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. Read SEC document
February 08, 2025 Filed Feb 11, 2025 17:13 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionCommon Stock	1,225	Not disclosed	Not disclosed	Disclosure SEC source: 0001555280-25-000085 · wk-form4_1739312010.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document
February 06, 2025 Filed Feb 10, 2025 09:24 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionRestricted Stock Unit · Derivative	1,236.2125	Not disclosed	Not disclosed	Disclosure SEC source: 0001555280-25-000043 · wk-form4_1739197473.xml · derivative · entry 6 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,236.2125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F5 · derivative.exercise_date: Each RSU vests and is settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 6, 2024. F6 · derivative.expiration_date: Not applicable. Read SEC document
February 06, 2025 Filed Feb 10, 2025 09:24 UTC	Zoetis Inc. ZTS · Entity 679	OtherCommon Stock	310	$174.12	$53,977.20	Disclosure SEC source: 0001555280-25-000043 · wk-form4_1739197473.xml · nonDerivative · entry 2 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 926 F2 · kind: Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. Read SEC document
February 06, 2025 Filed Feb 10, 2025 09:24 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionCommon Stock	1,236	Not disclosed	Not disclosed	Disclosure SEC source: 0001555280-25-000043 · wk-form4_1739197473.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document
June 07, 2024 Filed Jun 10, 2024 20:21 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	9,293	$0.00	$0.00	Disclosure SEC source: 0001802768-24-000038 · wk-form4_1718050892.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,738 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document
June 05, 2024 Filed Jun 6, 2024 22:55 UTC	Praxis Precision Medicines, Inc. PRAX · Entity 3538	GrantStock Option (Right to Buy) · Derivative	8,566	$0.00 Strike: $44.25	$0.00	Disclosure SEC source: 0001689548-24-000074 · wk-form4_1717714512.xml · derivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,566 Underlying: Common Stock · 8,566 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 5, 2024. Read SEC document
May 06, 2024 Filed May 8, 2024 20:48 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionRestricted Stock Units · Derivative	41,133	$0.00	$0.00	Disclosure SEC source: 0001401708-24-000087 · wk-form4_1715215705.xml · derivative · entry 2 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F3 · derivative.exercise_date: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated. F3 · derivative.expiration_date: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated. Read SEC document
May 06, 2024 Filed May 8, 2024 20:48 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionCommon Stock	41,133	$0.00	$0.00	Disclosure SEC source: 0001401708-24-000087 · wk-form4_1715215705.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares have not been delivered to the reporting person. Read SEC document
February 21, 2024 Filed Feb 22, 2024 16:38 UTC	Zoetis Inc. ZTS · Entity 679	GiftCommon Stock	2,214	$0.00	$0.00	Disclosure SEC source: 0001555280-24-000189 · wk-form4_1708637873.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · balance_after: Amount of shares has been reduced by 1,218 shares to correct an inadvertent error in the number of shares listed in previous reports as directly held by the Reporting Person. Read SEC document
February 10, 2024 Filed Feb 13, 2024 17:10 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionRestricted Stock Unit · Derivative	1,463.3937	Not disclosed	Not disclosed	Disclosure SEC source: 0001555280-24-000171 · wk-form4_1707862229.xml · derivative · entry 6 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,212.3053 Underlying: Common Stock · 1,463.3937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F5 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. The RSUs vest as follows: 1,463.3937 RSUs vested on February 10, 2024; and 1,212.3053 RSUs will vest on February 8, 2025. F6 · derivative.expiration_date: Not applicable. F7 · balance_after: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, February 8, 2022; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Read SEC document
February 10, 2024 Filed Feb 13, 2024 17:10 UTC	Zoetis Inc. ZTS · Entity 679	OtherCommon Stock	367	$197.32	$72,416.44	Disclosure SEC source: 0001555280-24-000171 · wk-form4_1707862229.xml · nonDerivative · entry 2 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,432 F2 · kind: Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. Read SEC document
February 10, 2024 Filed Feb 13, 2024 17:10 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionCommon Stock	1,463	Not disclosed	Not disclosed	Disclosure SEC source: 0001555280-24-000171 · wk-form4_1707862229.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document
February 08, 2024 Filed Feb 12, 2024 17:57 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionRestricted Stock Unit · Derivative	1,493.2652	Not disclosed	Not disclosed	Disclosure SEC source: 0001555280-24-000135 · wk-form4_1707778606.xml · derivative · entry 6 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,493.2652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F7 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 8, 2023; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F8 · derivative.expiration_date: Not applicable. Read SEC document
February 08, 2024 Filed Feb 12, 2024 17:57 UTC	Zoetis Inc. ZTS · Entity 679	OtherCommon Stock	375	$195.75	$73,406.25	Disclosure SEC source: 0001555280-24-000135 · wk-form4_1707778606.xml · nonDerivative · entry 2 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,336 F2 · kind: Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. Read SEC document
February 08, 2024 Filed Feb 12, 2024 17:57 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionCommon Stock	1,493	Not disclosed	Not disclosed	Disclosure SEC source: 0001555280-24-000135 · wk-form4_1707778606.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document
February 06, 2024 Filed Feb 8, 2024 16:36 UTC	Zoetis Inc. ZTS · Entity 679	GrantRestricted Stock Unit · Derivative	1,223	$0.00	$0.00	Disclosure SEC source: 0001555280-24-000086 · wk-form4_1707428174.xml · derivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,223 Underlying: Common Stock · 1,223 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 6, 2024; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. Read SEC document
June 23, 2023 Filed Jun 26, 2023 20:12 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	7,747	$0.00	$0.00	Disclosure SEC source: 0001209191-23-039691 · doc4.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,445 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document
June 23, 2023 Filed Jun 27, 2023 17:48 UTC	NanoString Technologies Inc NSTG · Entity 15988	GrantRestricted Stock Units · Derivative	41,133	$0.00	$0.00	Disclosure SEC source: 0001401708-23-000175 · wf-form4_168790252404412.xml · derivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,133 Underlying: Common Stock · 41,133 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F2 · derivative.exercise_date: 100% of the RSUs vest on the earlier of the one year anniversary of June 23, 2023 or on the date immediately prior to the 2024 annual meeting of stockholders. F2 · derivative.expiration_date: 100% of the RSUs vest on the earlier of the one year anniversary of June 23, 2023 or on the date immediately prior to the 2024 annual meeting of stockholders. Read SEC document
June 17, 2023 Filed Jun 20, 2023 16:19 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionCommon Stock · Derivative	14,851	$0.00	$0.00	Disclosure SEC source: 0001401708-23-000147 · wf-form4_168729236052751.xml · derivative · entry 2 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,851 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F2 · derivative.exercise_date: 100% of the RSUs vest on the earlier of the one year anniversary of June 17, 2022 or on the date immediately prior to the 2023 annual meeting of stockholders. F2 · derivative.expiration_date: 100% of the RSUs vest on the earlier of the one year anniversary of June 17, 2022 or on the date immediately prior to the 2023 annual meeting of stockholders. Read SEC document
June 17, 2023 Filed Jun 20, 2023 16:19 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionCommon Stock	14,851	$0.00	$0.00	Disclosure SEC source: 0001401708-23-000147 · wf-form4_168729236052751.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 12, 2023 Filed Jun 14, 2023 11:12 UTC	Praxis Precision Medicines, Inc. PRAX · Entity 3538	GrantStock Option (Right to Buy) · Derivative	28,981	$0.00 Strike: $0.96	$0.00	Disclosure SEC source: 0001689548-23-000107 · wf-form4_168674116209042.xml · derivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,981 Underlying: Common Stock · 28,981 shares Expires 2033-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 12, 2023. Read SEC document
May 19, 2023 Filed May 22, 2023 16:30 UTC Amendment	Zoetis Inc. ZTS · Entity 679	GiftCommon Stock	2,659	$0.00	$0.00	Disclosure SEC source: 0001555280-23-000163 · wf-form4a_168478744037299.xml · nonDerivative · entry 3 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By personal trust Disclosed balance after: 583.1922 F1 · date: This amended report is being filed solely to correct an error in the transaction dates for the reported transactions due to broker administrative error. Read SEC document
May 15, 2023 Filed May 22, 2023 16:30 UTC Amendment	Zoetis Inc. ZTS · Entity 679	GiftCommon Stock	2,659	$0.00	$0.00	Disclosure SEC source: 0001555280-23-000163 · wf-form4a_168478744037299.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By personal trust Disclosed balance after: 3,242.1922 F1 · date: This amended report is being filed solely to correct an error in the transaction dates for the reported transactions due to broker administrative error. Read SEC document
May 05, 2023 Filed May 8, 2023 16:23 UTC	Zoetis Inc. ZTS · Entity 679	GiftCommon Stock	5,318	$0.00	$0.00	Disclosure SEC source: 0001555280-23-000153 · wf-form4_168357740645481.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By personal trust Disclosed balance after: 583.1922 Read SEC document
April 27, 2023 Filed Apr 28, 2023 19:22 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionStock Option (right to buy) · Derivative	8,768	$8.45 Strike: $8.45	$74,089.60	Disclosure SEC source: 0001401708-23-000100 · wf-form4_168272414154950.xml · derivative · entry 2 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,768 shares Expires 2023-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 50% of the total shares subject to the Option shall vest on the one year anniversary of June 25, 2013, and the remaining 50% of the total shares shall vest in twelve equal monthly installments thereafter. The vesting of shares subject to the Option will accelerate in full upon a "change in control" as defined in the 2013 Equity Incentive Plan. Read SEC document
April 27, 2023 Filed Apr 28, 2023 19:22 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionCommon Stock	8,768	$8.45	$74,089.60	Disclosure SEC source: 0001401708-23-000100 · wf-form4_168272414154950.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 07, 2023 Filed Mar 8, 2023 16:08 UTC	NanoString Technologies Inc NSTG · Entity 15988	PurchaseCommon Stock	12,500	$9.84	$123,000.00	Disclosure SEC source: 0001401708-23-000074 · wf-form4_167830969664310.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,800 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were sold in multiple transactions at prices ranging from $9.81 to $9.86, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document
February 11, 2023 Filed Feb 14, 2023 16:54 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionRestricted Stock Unit · Derivative	1,626.8438	Not disclosed	Not disclosed	Disclosure SEC source: 0001555280-23-000100 · wf-form4_167641165501078.xml · derivative · entry 6 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,651.9299 Underlying: Common Stock · 1,626.8438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 1,450.3939 RSUs will vest on February 10, 2024; and 1,201.5360 RSUs will vest on February 8, 2025. F1 · derivative.exercise_price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. F5 · derivative.exercise_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 1,450.3939 RSUs will vest on February 10, 2024; and 1,201.5360 RSUs will vest on February 8, 2025. F6 · derivative.expiration_date: Not applicable. F5 · balance_after: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 1,450.3939 RSUs will vest on February 10, 2024; and 1,201.5360 RSUs will vest on February 8, 2025. Read SEC document
February 11, 2023 Filed Feb 14, 2023 16:54 UTC	Zoetis Inc. ZTS · Entity 679	OtherCommon Stock	408	$158.33	$64,598.64	Disclosure SEC source: 0001555280-23-000100 · wf-form4_167641165501078.xml · nonDerivative · entry 2 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,218 F2 · kind: Disposition of shares to the Company in exchange for cash based on the closing share price of Zoetis Inc. common stock as of the vesting date. Read SEC document
February 11, 2023 Filed Feb 14, 2023 16:54 UTC	Zoetis Inc. ZTS · Entity 679	Exercise / conversionCommon Stock	1,626	Not disclosed	Not disclosed	Disclosure SEC source: 0001555280-23-000100 · wf-form4_167641165501078.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU. Read SEC document
February 08, 2023 Filed Feb 10, 2023 18:29 UTC	Zoetis Inc. ZTS · Entity 679	GrantRestricted Stock Unit · Derivative	1,480	$0.00	$0.00	Disclosure SEC source: 0001555280-23-000062 · wf-form4_167607177536809.xml · derivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,480 Underlying: Common Stock · 1,480 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). RSUs vest and are settled in shares of Zoetis common stock on the first anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. Read SEC document
June 24, 2022 Filed Jun 24, 2022 20:59 UTC	Royalty Pharma plc RPRX · Entity 3100	GrantClass A Ordinary Shares	6,328	$0.00	$0.00	Disclosure SEC source: 0000899243-22-024045 · doc4.xml · nonDerivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,698 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.